Vertex Pharmaceuticals Logo

Email this page: News Release

Vertex Announces Positive Results from Open-Label Phase 3 Study of KALYDECO® (ivacaftor) in Children with Cystic Fibrosis Ages 1 to 2 Years

For security reasons, registration is required before you can use this feature.
* Indicates required field